ESR1 and neoplasm: Our results showed no significant correlation between 14-3-3 σ promoter methylation status and clinicopathological features, including age status, tumor grade, clinic stage, lymph node status, histological subtype, ER status, PR status, and HER2 status (all P > 0.1).